Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Antiretroviral therapy (ART) initiated in the acute phase of HIV infection (AHI) results in a smaller viral reservoir. However, the impact of early HIV-specific T-cell responses on long-term reservoir ...

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1 ...

Studies in both experimental animals and humans uniformly indicate that a large gradient exists between plasma and CSF insulin concentrations in healthy individuals, with plasma concentrations ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second ...

The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk ...

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

According to the company, VTX3232 showed an excellent PK profile, exceeding the IC₉₀ for NLRP3 inhibition. A high correlation between plasma and CSF exposures was observed.

Distribution of plasma versus CSF AD biomarkers concentrations stratified by CSF p-tau181/Aβ42 status. (CREDIT: Alzheimer's and Dementia) ...